Article
Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2011
Beau-Faller Michèle, Degeorges Armelle, Rolland Estelle, Mounawar Mounia, Antoine Martine, Poulot Virginie, Mauguen Audrey, Barbu Véronique, Coulet Florence, Prétet Jean-Luc, Bièche Ivan, Blons Hélène, Boyer Jean-Christophe, Buisine Marie-Pierre, de Fraipont Florence, Lizard Sarab, Olschwang Sylviane, Saulnier Patrick, Prunier-Mirebeau Delphine, Richard Nicolas, Danel Claire, Brambilla Elisabeth, Chouaid Christos, Zalcman Gérard, Hainaut Pierre, Michiels Stefan, Cadranel Jacques
Abstract excerpt
INTRODUCTION: The Evaluation of the epidermal growth factor receptor (EGFR) Mutation status for the administration of EGFR-Tyrosine Kinase Inhibitors in non-small cell lung Carcinoma (NSCLC) (ERMETIC) project part 1 assessed the accuracy of EGFR and KRAS mutations detection in NSCLC among 15 French centers. METHODS: The 15 ERMETIC centers selected 74 NSCLC surgical specimens from previously untreated patients....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.